The information required by this item is incorporated by reference to the information set forth in the sections titled "Proposal 1 —Election of Directors," "Information Regarding the Board of Directors and Corporate Governance," and "Information Regarding Executive Officers," which will be included in our definitive proxy statement for our 2024 Annual Meeting of Shareholders (the "2024 Proxy Statement"), if the 2024 Proxy Statement is filed with the SEC within 120 days after December 31, 2023, or will other ...

biote Corp. (OTCPK:FSNUF) Q4 2023 Earnings Conference Call March 12, 2024 5:00 PM ET Company Participants Simon Serowiecki - Investor Relations Terry Weber - Chief Executive Officer Bob Peterson - Chief Financial Officer Marc Beer - Executive Chairman Dr. Ross McQuivey - Chief Medical Officer Conference Call Participants Les Sulewski - Truist Securities Jonna Kim - TD Cowen Richard Magnusen - B. Riley & Co. Kaumil Gajrawala - Jefferies Operator Good afternoon, and welcome to the biote Fourth Quarter and Ful ...

The market expects biote Corp. (BTMD) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be release ...

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced it has signed a binding term sheet with Dr. Gary S. Donovitz (“Donovitz”), founder and stockholder of Biote, to resolve outstanding litigation. In connection with this agreement, Biote will repurchase all of the Class A common units of Biote Holdings, LLC (“Holdings Uni ...

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that its Board of Directors has approved a $20 million share repurchase program of the Company's common stock. This approval grants Biote’s management the authority to repurchase outstanding shares of the Company’s common stock, from time to time, in the open market, in ...

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that management expects 2023 revenue and Adjusted EBITDA to be slightly below prior guidance. The Company had previously forecast that revenue and Adjusted EBITDA would be toward the lower end of the previously announced ranges of $190-$200 million and $56-$60 million, ...

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced a definitive agreement to acquire F.H. Investments, Inc., d/b/a Asteria Health, a privately held 503B manufacturer of compounded bioidentical hormones. The company operates an FDA-registered 503B outsourcing facility in Birmingham, Alabama and currently supports Biote-c ...

(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR Table of Contents PART II. OTHER INFORMATION 40 This Quarterly Report on Form 10-Q (this "Quarterly Report") contains forward-looking statements. These forward-looking statements relate to expectations for future financial performance, business strategies, or expectations for the Company's business. These forward-looking statements include, but are not lim ...

Prepaid expenses include software and technology licensing agreements, insurance premiums and other advance payments for services to be received over the next 12 months. Advances are comprised of deposit payments to vendors for inventory purchase orders to be received in the next 12 months. Other assets consist of interest earned on the Company's short-term investment as well as on its money market account. Impairment of Long-Lived Assets—Long-lived assets, such as property and equipment and capitalized sof ...

Selling, General and Administrative Expense | --- | --- | --- | --- | --- | --- | --- | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------|-------|-------|-------------|-------|----------|-------|-------------|-------------| | (U.S. dollars, in thousands) \nRevenue: | | | 2023 | | 2022 | | $ | % | | Product revenue | $ | | 44,155 | $ | 36,758 | $ | 7,397 | 20.1 % | | Service revenue | | | 688 | | 385 | | 303 ...